

## Special Issue

# Drug Discovery: Genomic and Transcriptomic Approaches

### Message from the Guest Editor

With the development of sequencing capability and bioinformatics analytic tools, omics have become an indispensable tool in modern drug discovery. High-throughput data such as genomic, epigenetic, transcriptomic, proteomic, metabolomic, and ribosome profiling data as well as single-cell sequencing have all made significant contributions to mechanism-based drug discovery and drug repurposing. Omics data analysis can not only accelerate drug target identification and drug candidate screening but can also facilitate the characterization of side effects and predict drug resistance. For this Special Issue, we encourage the use of omics data for drug-discovery-related exploration, aiming to provide a forum for advances in the development and application of omics-based drug-discovery strategies.

---

### Guest Editor

Prof. Dr. Keshen Li  
Department of Neurology, Jinan University, Guangzhou, China

---

### Deadline for manuscript submissions

closed (31 May 2023)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/151075](https://mdpi.com/si/151075)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)